“…Signaling pathways include cytokine signaling in immune system [48], extracellular matrix organization [49], diseases of metabolism [50], hemostasis [51], innate immune system [52], metabolism of lipids [53] and metabolism [54] were linked with progression of PCOS. Altered expression of PLA2G5 [55], CASP1 [56], EDNRA (endothelin receptor type A) [57], F2RL1 [58], FOXP3 [59], DRD4 [60], COL6A3 [61], TIMP4 [62], SOCS1 [63], CD74 [64], TGFB1 [65], ATF5 [66], IRF7 [67], IRX3 [68], FOXC2 [69], STX1A [70], IL1RL1 [71], HHIP (hedgehog interacting protein) [72], ELOVL2 [73], BGN (biglycan) [74], POMC (proopiomelanocortin) [75], DOK5 [76], COL1A1 [77], POSTN (periostin) [78], SOD3 [79], ZNF423 [80], FABP5 [81], DDIT4 [82], KCTD15 [83], COL1A2 [84], MGAT2 [85], ENDOG (endonuclease G) [86], HSPA5 [87], CES1 [88], CYP19A1 [89], PLAC8 [90], CD36 [91], GIPR (gastric inhibitory polypeptide receptor) [92], ARG1 [93], MSR1 [94], DOCK2 [95], S1PR1 [96], OXTR (oxytocin receptor) [97], F11R [98], LEPR (leptin receptor) [99], AR (androgen receptor) [100], DKK3 [101], FOXO1 [102], PIK3CB [103], WWP1 [104], PHIP (pleckstrin homology domain interacting protein) [105], MPZL3 [106], FBXO2 [107], GUCY2C [108], ADRA2A [109], CHRNA5 [110], GLP2R [111], SDC3 [112], NFAT5 [113], PON2 [114], PRNP (prion protein) [115], DGKE (diacylglycerol kinase epsilon) [116], ARHGAP21 [117], COQ2 [118], EPHX2 [119] and FAM3C […”